In last trading session, Pyxis Oncology Inc (NASDAQ:PYXS) saw 0.51 million shares changing hands with its beta currently measuring 1.11. Company’s recent per share price level of $1.11 trading at $0.04 or 3.74% at ring of the bell on the day assigns it a market valuation of $66.01M. That closing price of PYXS’s stock is at a discount of -456.76% from its 52-week high price of $6.18 and is indicating a premium of 10.81% from its 52-week low price of $0.99. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 690.33K if we extend that period to 3-months.
For Pyxis Oncology Inc (PYXS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.33 in the current quarter.
Pyxis Oncology Inc (NASDAQ:PYXS) trade information
Upright in the green during last session for gaining 3.74%, in the last five days PYXS remained trading in the red while hitting it’s week-highest on Thursday, 03/13/25 when the stock touched $1.11 price level, adding 3.48% to its value on the day. Pyxis Oncology Inc’s shares saw a change of -28.85% in year-to-date performance and have moved -4.31% in past 5-day. Pyxis Oncology Inc (NASDAQ:PYXS) showed a performance of -13.28% in past 30-days. Number of shares sold short was 7.01 million shares which calculate 10.14 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 10 to the stock, which implies a rise of 88.9% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -530.63% in reaching the projected high whereas dropping to the targeted low would mean a loss of -530.63% for stock’s current value.
Pyxis Oncology Inc (PYXS) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -118.72% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 40.99% while estimates for its earnings growth in next 5 years are of 12.25%.
Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders
Insiders are in possession of 24.57% of company’s total shares while institution are holding 41.52 percent of that, with stock having share float percentage of 55.04%. Investors also watch the number of corporate investors in a company very closely, which is 41.52% institutions for Pyxis Oncology Inc that are currently holding shares of the company. DEEP TRACK CAPITAL, LP is the top institutional holder at PYXS for having 4.18 million shares of worth $13.85 million. And as of 2024-06-30, it was holding 6.9164 of the company’s outstanding shares.
The second largest institutional holder is LAURION CAPITAL MANAGEMENT LP, which was holding about 3.86 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.3826 of outstanding shares, having a total worth of $12.78 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.29 shares of worth $1.44 million or 2.18% of the total outstanding shares. The later fund manager was in possession of 1.29 shares on Dec 31, 2024 , making its stake of worth around $1.43 million in the company or a holder of 2.17% of company’s stock.
